Date | Open(₹) | High(₹) | Low(₹) | Close(₹) | No. Of Trades(₹) | Total Turnover(₹) | Deliverable Quantity(₹) |
|---|---|---|---|---|---|---|---|
29-Dec-2025 | 2,675 | 2,698.3 | 2,666.4 | 2,690.2 | 11,036 | 15,89,63,685.5 | 30,009 |
30-Dec-2025 | 2,702.4 | 2,784.8 | 2,702.4 | 2,726.9 | 32,409 | 55,35,52,336.6 | 74,649 |
31-Dec-2025 | 2,726.9 | 2,777.6 | 2,710 | 2,768.9 | 13,130 | 21,28,61,237.8 | 44,592 |
01-Jan-2026 | 2,787.6 | 2,962 | 2,744.8 | 2,938.4 | 54,004 | 1,80,19,12,540.2 | 1,11,635 |
02-Jan-2026 | 2,937 | 3,020.8 | 2,902.8 | 2,949.2 | 34,716 | 85,73,29,745.3 | 1,03,487 |
05-Jan-2026 | 2,977.4 | 2,989.9 | 2,897 | 2,912.8 | 33,925 | 45,05,10,461.7 | 87,595 |
06-Jan-2026 | 2,912.1 | 2,912.1 | 2,790.4 | 2,844.4 | 41,952 | 89,34,21,028.7 | 1,91,474 |
07-Jan-2026 | 2,840 | 2,885 | 2,824.4 | 2,854 | 19,819 | 57,01,16,503.6 | 1,40,533 |
08-Jan-2026 | 2,861 | 2,875 | 2,814.2 | 2,838.4 | 14,028 | 55,16,60,224.4 | 1,42,651 |
09-Jan-2026 | 2,849.2 | 2,852.3 | 2,753 | 2,764.6 | 13,547 | 46,05,16,178.6 | 1,13,777 |
12-Jan-2026 | 2,758.1 | 2,759.7 | 2,682.7 | 2,729.5 | 15,566 | 19,03,92,678.1 | 39,313 |
13-Jan-2026 | 2,738 | 2,764.7 | 2,702 | 2,730.6 | 8,210 | 11,51,71,537.3 | 19,451 |
14-Jan-2026 | 2,739 | 2,739 | 2,659.4 | 2,706.4 | 29,239 | 57,45,66,892.3 | 1,29,302 |
16-Jan-2026 | 2,706.4 | 2,720.5 | 2,660.1 | 2,680.9 | 14,014 | 16,52,86,371.6 | 33,394 |
19-Jan-2026 | 2,680.1 | 2,720.9 | 2,654.5 | 2,685.6 | 7,309 | 9,45,76,985 | 13,755 |
20-Jan-2026 | 2,684 | 2,703.4 | 2,660.4 | 2,684.2 | 10,784 | 18,15,49,436 | 37,583 |
21-Jan-2026 | 2,679 | 2,723.6 | 2,666.4 | 2,713.1 | 20,240 | 52,82,16,018.2 | 1,30,842 |
22-Jan-2026 | 2,719 | 2,762.3 | 2,709.1 | 2,717.6 | 7,467 | 12,84,57,636.8 | 20,611 |
23-Jan-2026 | 2,715 | 2,717.4 | 2,672.1 | 2,699.6 | 10,516 | 19,73,54,292.6 | 47,365 |
The company plans to launch the product after securing all necessary regulatory approvals, which are expected to be received between late 2026 and early 2027.
Ajanta Pharma reported a strong EBITDA margin of 25% in the quarter.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund & Specialized Investment Fund Distributor), PFRDA Reg. No. PoP 20092018
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
